OXFORD - Despite shrugs from the market, Vanguard Medica Group plc believes that its submission of a U.S. NDA for its Miguard frovatriptan migraine treatment is a testament to the company's virtually integrated business model.
CEO Robert Mansfield told BioCentury that the company completed the development of frovatriptan in four and a quarter years compared with the industry norm of six years through the same stages. He anticipates adding to last week's FDA filing with a European application in the near future.
see Ebb & Flow, A16), market reaction to the NDA news was muted. VGD gained 3.5p (2 percent) to 163.5p. In the past year, the